Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatostatin for prevention of post-ERCP pancreatitis
ChiCTR-PRC-09000449Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of somatostatin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Serum amylase concentration and Serum lipase concentration. Started Dec 2008; status: recruiting.
02
Drugs
somatostatin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on ChiCTR-PRC-09000449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-09000449.